Abstract
An increasing number of reports indicate that endogenously produced inhibitors of nitric oxide synthase, particularly asymmetric dimethylarginine (ADMA), regulate nitric oxide generation in disease states. This article describes the biology of ADMA and the implications for cardiovascular physiology and pathophysiology.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Amidohydrolases / antagonists & inhibitors
-
Amidohydrolases / metabolism*
-
Animals
-
Arginine / analogs & derivatives*
-
Arginine / metabolism*
-
Cardiovascular Diseases / drug therapy
-
Cardiovascular Diseases / metabolism
-
Cardiovascular Diseases / physiopathology*
-
Cardiovascular Physiological Phenomena*
-
Diabetes Mellitus / metabolism
-
Endothelium, Vascular / metabolism
-
Endothelium, Vascular / physiopathology
-
Enzyme Inhibitors / therapeutic use
-
Female
-
Humans
-
Mice
-
Models, Biological
-
Nitric Oxide / metabolism
-
Nitric Oxide Synthase / antagonists & inhibitors
-
Pre-Eclampsia / metabolism
-
Pregnancy
-
Protein-Arginine N-Methyltransferases / metabolism
-
Renal Insufficiency / metabolism
-
omega-N-Methylarginine / pharmacology
Substances
-
Enzyme Inhibitors
-
omega-N-Methylarginine
-
Nitric Oxide
-
N,N-dimethylarginine
-
Arginine
-
Nitric Oxide Synthase
-
Protein-Arginine N-Methyltransferases
-
Amidohydrolases
-
dimethylargininase